In the past week, ALZN stock has gone up by 0.68%, with a monthly decline of -23.24% and a quarterly plunge of -68.59%. The volatility ratio for the week is 4.87%, and the volatility levels for the last 30 days are 6.63% for Alzamend Neuro Inc The simple moving average for the past 20 days is -5.72% for ALZN’s stock, with a -68.30% simple moving average for the past 200 days.
Is It Worth Investing in Alzamend Neuro Inc (NASDAQ: ALZN) Right Now?
Additionally, the 36-month beta value for ALZN is -0.32. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 1 rating it as “hold”, and 0 rating it as “sell”.
The public float for ALZN is 0.78M and currently, short sellers hold a 17.45% ratio of that float. The average trading volume of ALZN on July 04, 2025 was 1.62M shares.
ALZN stock’s latest price update
Alzamend Neuro Inc (NASDAQ: ALZN)’s stock price has gone decline by -2.00% in comparison to its previous close of $3.0, however, the company has experienced a 0.68% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-16 that ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) — Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the “Agreement”) with a sophisticated investor (the “Investor”), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase shares of Alzamend’s common stock for a total purchase price of up to $5 million, less a five percent (5%) discount (the “Financing”) in seven monthly tranche closings (a “Tranche Closing”), starting in April 2025, with the Investor having the ability, in its sole discretion, to purchase Preferred Stock prior to the dates set for each Tranche Closing.
Analysts’ Opinion of ALZN
Many brokerage firms have already submitted their reports for ALZN stocks, with Ascendiant Capital Markets repeating the rating for ALZN by listing it as a “Buy”. The predicted price for ALZN in the upcoming period, according to Ascendiant Capital Markets is $8 based on the research report published on October 01, 2021 of the previous year 2021.
ALZN Trading at -27.91% from the 50-Day Moving Average
After a stumble in the market that brought ALZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.83% of loss for the given period.
Volatility was left at 6.63%, however, over the last 30 days, the volatility rate increased by 4.87%, as shares sank -25.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.66% lower at present.
During the last 5 trading sessions, ALZN rose by +0.68%, which changed the moving average for the period of 200-days by -83.07% in comparison to the 20-day moving average, which settled at $3.12. In addition, Alzamend Neuro Inc saw -92.01% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALZN starting from AULT MILTON C III, who sold 1,213 shares at the price of $5.06 back on May 12 ’25. After this action, AULT MILTON C III now owns 8,260 shares of Alzamend Neuro Inc, valued at $6,138 using the latest closing price.
AULT MILTON C III, the Director of Alzamend Neuro Inc, sale 11 shares at $5.28 during a trade that took place back on May 12 ’25, which means that AULT MILTON C III is holding 1,843 shares at $58 based on the most recent closing price.
Stock Fundamentals for ALZN
Current profitability levels for the company are sitting at:
- -55.29% for the present operating margin
- 0.67% for the gross margin
The net margin for Alzamend Neuro Inc stands at -55.54%. The total capital return value is set at -1.22%. Equity return is now at value -1092.96%, with -168.13% for asset returns.
Currently, EBITDA for the company is -9.89 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of -13.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.44.
Conclusion
In conclusion, Alzamend Neuro Inc (ALZN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
